Abstract
Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Graphical Abstract
Current Drug Discovery Technologies
Title:NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease
Volume: 12 Issue: 4
Author(s): C. Subathra Devi, V. Mohanasrinivasan, C. George Priyadoss, Nikhil Arora, Bharti Singh, Neetu Mittal, Shubham Agarwal and Shwetank Saxena
Affiliation:
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Abstract: Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Devi Subathra C., Mohanasrinivasan V., Priyadoss George C., Arora Nikhil, Singh Bharti, Mittal Neetu, Agarwal Shubham and Saxena Shwetank, NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease, Current Drug Discovery Technologies 2015; 12 (4) . https://dx.doi.org/10.2174/1570163813666151117121210
DOI https://dx.doi.org/10.2174/1570163813666151117121210 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
CNS & Neurological Disorders - Drug Targets The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Current Alzheimer Research Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Carotid Endarterectomy and Carotid Artery Stenting Lead to Improved Cognitive Performance in Patients with Severe Carotid Artery Stenosis
Current Neurovascular Research Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Serotonin Reuptake Inhibitors and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)